WUHAN, China, March 12, 2018 /PRNewswire/ — XW Laboratories Inc. (XW Labs) announced the initiation of a Phase 1 single ascending dose (SAD) study in healthy subjects in Australia for its novel proprietary compound XW10172 to assess safety, tolerability and pharmacokinetics. XW10172 is…
